Polygenic Embryo Screening: Where Do We Stand? – ESHRE
European Society of Human Reproduction and Embryology (ESHRE) shared a post on LinkedIn:
“Polygenic Embryo Screening: Where Do We Stand?
Polygenic embryo screening (PES) can now assess IVF embryos for risks of heart disease, diabetes, schizophrenia and cancers. It’s already available, but highly controversial.
The disconnect: patients show strong interest – healthcare professionals have serious concerns.
Join this ESHRE webinar as international experts share new research on these diverging attitudes. Through focused presentations and panel discussion, we’ll explore:
- What drives patient demand vs. professional hesitation
- How views differ across cultures and demographics
- The implications for policy, education and patient care
Be part of shaping how we navigate this emerging frontier in hashtag#ReproductiveGenetics.
Date: 10 February 2026 | 17:00 CET
Find out more.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 7, 2026, 16:23Amelia Degenkolb: ACOG 2026 Brings Innovation, Partnership and Patient Access Into Focus
-
May 7, 2026, 16:15New FIGO-IPPS Classification for Female Chronic Pelvic Pain – IJGO
-
May 7, 2026, 16:05Marco Zaccaria: How Uterine Fibroids Affect Latina Women
-
May 7, 2026, 12:36Adela Serban: Advanced Imaging Technique Enhances Uterine Imaging with 3D Ultrasound and Uterine Tracing
-
May 7, 2026, 12:26David Sable Highlights The Quest for Fertility as a Deep and Valuable Read
-
May 7, 2026, 12:20May Is Preeclampsia Awareness Month – The Society for Maternal-Fetal Medicine
-
May 7, 2026, 12:15PCOS Symptoms Should Not Be Dismissed – PCOS Awareness Association
-
May 7, 2026, 12:08Marco Zaccaria: The Role of the Junctional Zone in the Management of Adenomyosis With Infertility
-
May 7, 2026, 12:04Emad Sedeek: Understanding the Differences in PGT-A, PGT-M and PGT-P Embryogenetic Testing